CDK inhibitor E9
CAS No. 2020052-55-3
CDK inhibitor E9 ( E9 )
产品货号. M13145 CAS No. 2020052-55-3
CDK抑制剂E9是一种新型CDK抑制剂,可以克服ABC介导的THZ1耐药性,作为CDK9的有效非共价抑制剂和CDK12的共价抑制剂。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ¥2157 | 有现货 |
|
| 10MG | ¥94 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
| 1 mL x 10 mM in DMSO | ¥3468 | 有现货 |
|
生物学信息
-
产品名称CDK inhibitor E9
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述CDK抑制剂E9是一种新型CDK抑制剂,可以克服ABC介导的THZ1耐药性,作为CDK9的有效非共价抑制剂和CDK12的共价抑制剂。
-
产品描述CDK inhibitor E9 is a novel CDK inhibitor that can overcomes ABC-mediated resistance of THZ1, functions as a potent, non-covalent inhibitor of CDK9 and a covalent inhibitor of CDK12; does not serve as a substrate for either ABCB1 or ABCG2, while avoiding ABC transporter-mediated efflux; decreases the phosphorylated and total RNAPII in THZ1R NB and lung cancer cells (IC50=8-40 nM), accompanied by decreased MYC and MCL1 expression, exerts its cytotoxic effects through covalent modification of cysteine 1039 of CDK12.
-
体外实验CDK12-IN-E9 (E9; 10 nM-10 μM; 72 hours; Kelly, LAN5, SK-N-BE2, PC-9, NCI-H82 and NCI-H3122 cells) treatment shows potent antiproliferative activity in THZ1R NB and lung cancer cells, with IC50 values ranging from 8 to 40 nM.CDK12-IN-E9 (E9; 0-3000 nM; 6 hours; Kelly, PC-9, and NCI-H82 cells) treatment leads to a dose-dependent decrease in phosphorylated and total RNAPII in THZ1r NB and lung cancer models, accompanied by decreased MYC and MCL1 expression.CDK12-IN-E9 also results in increased PARP cleavage, and an increase in the subGI population in THZ1r lung cancer cells, while in NB cells, more of a G2/M arrest is seen after a 24-hr exposure to CDK12-IN-E9. Cell Proliferation Assay Cell Line:Kelly, LAN5, SK-N-BE2, PC-9, NCI-H82 and NCI-H3122 cells Concentration:10 nM-10 μM Incubation Time:72 hours Result:Showed potent antiproliferative activity in THZ1R NB and lung cancer cells, with IC50 values ranging from 8 to 40 nM.Western Blot Analysis Cell Line:Kelly, PC-9, and NCI-H82 cells Concentration:0 nM, 30 nM, 100 nM, 300 nM, 1000 nM, 3000 nM Incubation Time:6 hours Result:Led to a dose-dependent decrease in phosphorylated and total RNAPII in THZ1r NB and lung cancer models.
-
体内实验——
-
同义词E9
-
通路Angiogenesis
-
靶点CDK
-
受体CDK
-
研究领域——
-
适应症——
化学信息
-
CAS Number2020052-55-3
-
分子量434.544
-
分子式C24H30N6O2
-
纯度>98% (HPLC)
-
溶解度In Vitro:?DMSO : 125 mg/mL (287.67 mM)
-
SMILESC=CC(NC1=CC=CC(NC2=CC(N3[C@H](CCO)CCCC3)=NC4=C(CC)C=NN24)=C1)=O
-
化学全称(S)-N-(3-((3-ethyl-5-(2-(2-hydroxyethyl)piperidin-1-yl)pyrazolo[1,5-a]pyrimidin-7-yl)amino)phenyl)acrylamide
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Gao Y, et al. Cell Chem Biol. 2018 Feb 15;25(2):135-142.e5.
产品手册
关联产品
-
CDK12 inhibitor 2
CDK12抑制剂2是一种有效的、选择性的、非共价CDK12抑制剂,IC50为52 nM,选择性是CDK2/7/8/9的192倍以上。
-
NU-6027
NU-6027 (NU6027) 是 CDK1 和 CDK2 的 ATP 竞争性抑制剂,Ki 分别为 2.5 uM 和 1.3 uM。
-
CDK4/6-IN-2
CDK4/6-IN-2 是一种有效的 CDK4 和 CDK6 抑制剂(IC50:2.7 和 16 nM),源自专利 US20180000819A1(化合物 1)。
021-51111890
购物车()
sales@molnova.cn

